NO2016024I2 - Pharmaceutical composition or association containing as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - Google Patents

Pharmaceutical composition or association containing as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof

Info

Publication number
NO2016024I2
NO2016024I2 NO2016024C NO2016024C NO2016024I2 NO 2016024 I2 NO2016024 I2 NO 2016024I2 NO 2016024 C NO2016024 C NO 2016024C NO 2016024 C NO2016024 C NO 2016024C NO 2016024 I2 NO2016024 I2 NO 2016024I2
Authority
NO
Norway
Prior art keywords
salt
avibactam
ceftazidime
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
NO2016024C
Other languages
Norwegian (no)
Other versions
NO2016024I1 (en
Original Assignee
Astra Zeneca Holding France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2016024(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Zeneca Holding France filed Critical Astra Zeneca Holding France
Publication of NO2016024I1 publication Critical patent/NO2016024I1/en
Publication of NO2016024I2 publication Critical patent/NO2016024I2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
NO2016024C 2002-01-28 2016-12-15 Pharmaceutical composition or association containing as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof NO2016024I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (en) 2002-01-28 2002-01-28 NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
PCT/FR2003/000243 WO2003063864A2 (en) 2002-01-28 2003-01-27 Heterocyclic compounds which are active as inhibitors of beta lactamases

Publications (2)

Publication Number Publication Date
NO2016024I1 NO2016024I1 (en) 2016-12-15
NO2016024I2 true NO2016024I2 (en) 2016-12-15

Family

ID=27619669

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20043587A NO335195B1 (en) 2002-01-28 2004-08-27 Use of heterocyclic compounds which are active as inhibitors of beta-lactamases and their pharmaceutical composition.
NO2016024C NO2016024I2 (en) 2002-01-28 2016-12-15 Pharmaceutical composition or association containing as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20043587A NO335195B1 (en) 2002-01-28 2004-08-27 Use of heterocyclic compounds which are active as inhibitors of beta-lactamases and their pharmaceutical composition.

Country Status (45)

Country Link
US (4) US7612087B2 (en)
EP (2) EP1480644B1 (en)
JP (1) JP4472346B2 (en)
KR (1) KR100979079B1 (en)
CN (3) CN100563653C (en)
AR (2) AR038234A1 (en)
AT (1) ATE484281T1 (en)
AU (1) AU2003214335B2 (en)
BE (1) BE2016C069I2 (en)
BR (1) BRPI0307267B8 (en)
CA (1) CA2474043C (en)
CL (1) CL2011000009A1 (en)
CO (1) CO5601014A2 (en)
CR (2) CR7387A (en)
CY (3) CY1111061T1 (en)
DE (1) DE60334527D1 (en)
DK (2) DK2279737T3 (en)
EA (1) EA007220B1 (en)
EC (1) ECSP045193A (en)
ES (2) ES2401855T3 (en)
FR (1) FR2835186B1 (en)
HK (2) HK1077205A1 (en)
HR (1) HRP20040686B1 (en)
HU (1) HUS1600055I1 (en)
IL (1) IL163167A (en)
JO (1) JO2646B1 (en)
LT (1) LTC1480644I2 (en)
MA (1) MA26351A1 (en)
MX (1) MXPA04006621A (en)
MY (1) MY140638A (en)
NL (1) NL300847I2 (en)
NO (2) NO335195B1 (en)
NZ (1) NZ533936A (en)
OA (1) OA12761A (en)
PE (1) PE20030969A1 (en)
PL (1) PL220725B1 (en)
PT (2) PT1480644E (en)
RS (1) RS52137B (en)
SI (2) SI1480644T1 (en)
TN (1) TNSN04137A1 (en)
TW (1) TWI293071B (en)
UA (1) UA80271C2 (en)
UY (1) UY27626A1 (en)
WO (1) WO2003063864A2 (en)
ZA (1) ZA200405607B (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (en) * 2000-08-01 2002-10-11 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS
FR2835186B1 (en) * 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
FR2844273B1 (en) 2002-09-05 2008-04-04 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, METHOD AND INTERMEDIARY PREPARATION AND USE AS MEDICAMENT, IN PARTICULAR AS INHIBITORS OF BETA-LACTAMASES AND ANTI-BACTERIALS.
FR2848210B1 (en) * 2002-12-06 2007-10-19 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIALS AND INHIBITORS OF BETA-LACTAMASES
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
WO2007063552A1 (en) * 2005-12-02 2007-06-07 Lupin Limited Stable taste masked formulations of cephalosporins
KR101403164B1 (en) * 2005-12-07 2014-06-03 바실리어 파마슈티카 아게 Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
JP5539717B2 (en) * 2006-07-14 2014-07-02 塩野義製薬株式会社 Oxime compounds and uses thereof
JP2010507681A (en) * 2006-10-23 2010-03-11 アイアールエム・リミテッド・ライアビリティ・カンパニー Cathepsin protease inhibitor
US8563732B2 (en) * 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
FR2921060B1 (en) * 2007-09-14 2012-06-15 Novexel NOVEL PROCESS FOR PREPARING DISUBSIDED PIPERIDINE AND NOVEL INTERMEDIATES
RS53862B1 (en) * 2008-01-18 2015-08-31 Merck Sharp & Dohme Corp. Beta-lactamase inhibitors
US20110046101A1 (en) * 2008-03-17 2011-02-24 Dmitrienko Gary I Bate-lactamase inhibitors
FR2930553B1 (en) * 2008-04-29 2010-05-21 Novexel AZABICYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR BETA-LACTAMASES INHIBITORS
US8518934B2 (en) * 2008-06-11 2013-08-27 Shonogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
FR2936798B1 (en) * 2008-10-03 2012-09-28 Novexel NOVEL HETEROCYCLIC NITROGEN COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL MEDICINES.
FR2937034B1 (en) * 2008-10-10 2012-11-23 Novexel NOVEL HETEROCYCLIC NITROGEN COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL MEDICINES
FR2936951B1 (en) * 2008-10-10 2010-12-03 Novexel NOVEL COMBINATIONS OF ANTIBACTERIAL NITROGENIC HETEROCYCLIC COMPOUNDS WITH OTHER ANTIBACTERIAL COMPOUNDS AND THEIR USE AS MEDICAMENTS
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
FR2951171A1 (en) * 2009-10-09 2011-04-15 Novexel NOVEL SODIUM SALT OF A CRYSTALLIZED ENANTIOMER AZABICYCLIC COMPOUND AND NOVEL POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS AND THEIR PREPARATION
PT2603514T (en) 2010-08-10 2018-11-09 Rempex Pharmaceuticals Inc Cyclic boronic acid ester derivatives and therapeutic uses thereof
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
CA2822758C (en) * 2010-12-22 2018-03-20 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivative and process for preparing the same
CA2780403C (en) * 2011-06-17 2020-04-21 Forest Laboratories Holdings Ltd. Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
MX348974B (en) * 2011-08-27 2017-07-04 Wockhardt Ltd 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections.
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
BR112014003476A2 (en) * 2011-09-13 2017-03-01 Wockhardt Ltd nitrogen-containing compounds and their use
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
CA2868553A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole .beta.-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2014011825A (en) 2012-03-30 2015-02-20 Cubist Pharm Inc Isoxazole î²-lactamase inhibitors.
AR090539A1 (en) * 2012-04-02 2014-11-19 Astrazeneca Ab INHIBITING COMPOUNDS OF B LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
BR112014029368B1 (en) 2012-05-30 2020-10-27 Meiji Seika Pharma Co., Ltd beta-lactamase inhibitor and process to prepare the same
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112015003592B1 (en) * 2012-08-25 2020-04-14 Wockhardt Ltd 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
UA111925C2 (en) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894892A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014152996A1 (en) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
MY176278A (en) 2013-09-24 2020-07-27 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
EP3299370B1 (en) 2013-10-08 2021-11-24 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivative and production process thereof
CN106029068A (en) * 2014-02-20 2016-10-12 沃克哈特有限公司 Pharmaceutical combinations comprising antibacterial agents
CN103896936A (en) * 2014-03-20 2014-07-02 西安交通大学 (5S, 6R) cloxacillin penicilloate as well as preparation method and application thereof
DK3140310T3 (en) 2014-05-05 2019-10-21 Rempex Pharmaceuticals Inc SYNTHESIS OF BORONATE SALTS AND USE THEREOF
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
CA2947041A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104059083B (en) * 2014-05-27 2017-01-04 浙江工业大学 A kind of method of asymmetric synthesis of chirality bicyclo-caprolactam compounds
EP3164406A4 (en) 2014-07-01 2018-04-04 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
HUE044061T2 (en) 2014-11-17 2019-09-30 Entasis Therapeutics Ltd Combination therapy for treatment of resistant bacterial infections
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016088863A1 (en) 2014-12-05 2016-06-09 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN107580595B (en) * 2015-05-07 2020-09-18 拜欧蒂姆公司 Heterocyclic compounds and their use in the prevention or treatment of bacterial infections
MX2017013792A (en) * 2015-09-16 2018-07-06 Xuanzhu Pharma Co Ltd íŸ-LACTAMASE INHIBITOR AND APPLICATION THEREOF.
EA201890847A1 (en) 2015-10-02 2018-08-31 Легокем Байосайенсез, Инк. COMPOSITIONS AND METHODS FOR INHIBITING BETA LACTAMASE
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (en) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Dihydrooxadiazine compounds to treat infections and cancer
WO2018005662A1 (en) 2016-06-30 2018-01-04 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN106279163A (en) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 A kind of method synthesizing A Wei Batan and intermediate optical isomer thereof
CN107789355B (en) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 Compound pharmaceutical composition containing piperacillin and application thereof
PL3512851T3 (en) 2016-09-16 2022-11-14 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
JOP20190061A1 (en) * 2016-09-28 2019-03-26 Novartis Ag Beta-lactamase inhibitors
CN106699756B (en) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 The synthetic method of beta lactamase restrainer AVM hereinafter Batan
TW201831482A (en) 2017-02-06 2018-09-01 法商木塔比利斯公司 Novel heterocyclic compounds and their use in preventing or treating bacterial infections
EA038393B1 (en) 2017-05-08 2021-08-20 Энтасис Терапеутикс, Инк. Compounds and methods for treating bacterial infections
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
WO2019075084A1 (en) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
CN109678856B (en) * 2017-10-18 2020-09-25 新发药业有限公司 Preparation method of avibactam intermediate
TW201925201A (en) * 2017-11-10 2019-07-01 日商鹽野義製藥股份有限公司 Diazabicyclooctane derivatives
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (en) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 Beta-lactamase inhibitor urea-containing bicyclic compound and preparation method and application thereof
US20230365561A1 (en) * 2020-09-01 2023-11-16 Ningxia Academy Of Agricul Ture And Forestry Sciences Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
CN116375706A (en) * 2023-02-22 2023-07-04 时森海(杭州)医药科技有限公司 Abamectin sodium key intermediate and preparation method thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
DK0480939T3 (en) 1989-06-09 1995-07-10 Upjohn Co Heterocyclic amines with effect on the central nervous system
FR2676230B1 (en) 1991-05-07 1993-08-27 Centre Nat Rech Scient NOVEL PYRROLO [1,4] -BENZODIAZEPINES DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM.
JPH05339263A (en) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd Dihydropyridine derivative
ES2269528T3 (en) 1993-09-29 2007-04-01 Nabi NUCLEOSIDS AND NUCLEOTIDES WITH A HETEROCICLICAL RING.
US5854239A (en) * 1993-12-29 1998-12-29 Pfizer Inc. Diazabicyclic neuokinin antagonists
EP0702004A2 (en) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (en) 1995-12-22 1995-12-22 Astra Ab New Compounds
BR9612426A (en) * 1996-01-03 1999-07-13 Smithkline Beecham Plc Carbomoyloxy derivatives and their application as antibacterials
DE19627431A1 (en) 1996-07-08 1998-01-15 Bayer Ag Heterocyclically fused pyridines
UA51716C2 (en) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. combinations possessing hypotensive, cardioprotective, anti-ishemic, and antilipolytic agents, a pharmaceutical composition and METHOD OF TREATMENT
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (en) * 1997-10-29 2000-12-29 Smithkline Beecham Plc PLEUROMUTILINE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS
AU5265599A (en) 1998-04-08 1999-11-01 Takeda Chemical Industries Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
EP1091944A1 (en) 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
CZ20011900A3 (en) 1998-12-18 2002-02-13 Schering Corporation Substance, treatment method and pharmaceutical preparation in which the substance is comprised as well as use thereof for inhibition of farnesyl protein transferase
CO5180550A1 (en) 1999-04-19 2002-07-30 Smithkline Beecham Corp FAB I INHIBITORS
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
AU2001246893A1 (en) 2000-04-18 2001-10-30 Sumitomo Pharmaceuticals Company, Limited Tricyclic quinazolinediones
FR2812635B1 (en) * 2000-08-01 2002-10-11 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION AND USE AS MEDICAMENTS IN PARTICULAR AS ANTI-BACTERIALS
ATE361750T1 (en) 2001-02-22 2007-06-15 Univ London Pharmacy INDOLINES AND TETRAHYDRO-QUINOLINES AS PRODRUGS FOR TUMOR TREATMENT
FR2825705B1 (en) * 2001-06-08 2005-05-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIANS
FR2835186B1 (en) 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
CY2016042I2 (en) 2017-03-15
EP2279737B1 (en) 2012-10-31
HK1105864A1 (en) 2008-02-29
AR100790A2 (en) 2016-11-02
NO2016024I1 (en) 2016-12-15
DK2279737T3 (en) 2013-02-11
DE60334527D1 (en) 2010-11-25
LTPA2016037I1 (en) 2017-01-10
ES2401855T3 (en) 2013-04-25
EA200400981A1 (en) 2005-02-24
UA80271C2 (en) 2007-09-10
OA12761A (en) 2006-07-04
CN1655781A (en) 2005-08-17
US20090215747A1 (en) 2009-08-27
MA26351A1 (en) 2004-10-01
TWI293071B (en) 2008-02-01
US20050020572A1 (en) 2005-01-27
CY2016042I1 (en) 2017-03-15
CN101406471A (en) 2009-04-15
TNSN04137A1 (en) 2007-03-12
MXPA04006621A (en) 2004-10-04
WO2003063864A2 (en) 2003-08-07
CR20120356A (en) 2012-10-05
EP1480644A2 (en) 2004-12-01
CN100563653C (en) 2009-12-02
CL2011000009A1 (en) 2011-03-25
HK1077205A1 (en) 2006-02-10
NL300847I2 (en) 2017-01-03
FR2835186A1 (en) 2003-08-01
WO2003063864A3 (en) 2004-03-11
BE2016C069I2 (en) 2022-05-17
CA2474043C (en) 2011-08-02
BR0307267A (en) 2004-12-07
US20110245254A1 (en) 2011-10-06
ZA200405607B (en) 2005-09-28
ES2356813T3 (en) 2011-04-13
NO335195B1 (en) 2014-10-20
AR038234A1 (en) 2005-01-05
PE20030969A1 (en) 2003-12-12
TW200303305A (en) 2003-09-01
PL371601A1 (en) 2005-06-27
CY1114417T1 (en) 2016-08-31
FR2835186B1 (en) 2006-10-20
HRP20040686A2 (en) 2004-12-31
JP2005523897A (en) 2005-08-11
PL220725B1 (en) 2015-12-31
KR20040081473A (en) 2004-09-21
PT1480644E (en) 2011-01-17
ATE484281T1 (en) 2010-10-15
IL163167A (en) 2010-04-15
EP1480644B1 (en) 2010-10-13
SI2279737T1 (en) 2013-07-31
US7612087B2 (en) 2009-11-03
NO20043587L (en) 2004-08-27
EP2279737A1 (en) 2011-02-02
CN100482225C (en) 2009-04-29
LTC1480644I2 (en) 2018-09-10
UY27626A1 (en) 2003-08-29
MY140638A (en) 2010-01-15
NZ533936A (en) 2007-05-31
KR100979079B1 (en) 2010-08-31
HUS1600055I1 (en) 2017-01-30
CY1111061T1 (en) 2015-06-11
SI1480644T1 (en) 2011-03-31
CN1994301A (en) 2007-07-11
JP4472346B2 (en) 2010-06-02
YU65804A (en) 2006-08-17
AU2003214335B2 (en) 2007-04-05
US20100048528A1 (en) 2010-02-25
EA007220B1 (en) 2006-08-25
JO2646B1 (en) 2012-06-17
CA2474043A1 (en) 2003-08-07
RS52137B (en) 2012-08-31
BRPI0307267B1 (en) 2016-02-10
ECSP045193A (en) 2004-08-27
CO5601014A2 (en) 2006-01-31
CR7387A (en) 2010-10-25
HRP20040686B1 (en) 2013-02-28
PT2279737E (en) 2013-02-01
DK1480644T3 (en) 2011-01-24
BRPI0307267B8 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
NO2016024I2 (en) Pharmaceutical composition or association containing as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof
DK1538160T3 (en) Substituted isoquinoline-3-carboxylic acid amides, their preparation and their use as a drug
NO20004353D0 (en) New pyridazine derivatives and drugs containing these as active ingredients
NO993003D0 (en) Sulfonamide derivatives, processes for their preparation and their use as medicaments
NO2012006I1 (en) Telaprevir and any therapeutically equivalent form thereof protected by the basic patent, such as pharmaceutically acceptable salts and / or solvates of telaprevir or solvates of such salts
DK1095016T3 (en) Sulfur-substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical compositions comprising them
EE04815B1 (en) 6,9-Disubstituted-2- [trans- (4-aminocyclohexyl) amino] purines, pharmaceutical compositions containing them and their use
HUP0401567A3 (en) Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
NO20032438L (en) Orthosubstituted and metasubstituted bisaryl compounds, their method of preparation, their use as a drug, and pharmaceutical preparations containing the compounds
BR9911871B1 (en) phenoxyacetic acid derivatives and pharmaceutical compositions containing them.
FI970825A (en) Pharmaceutical compositions containing bile salt and buffer to increase the bioavailability of the active compound
NO20011503L (en) Indeno-, naphtho- and benzocyclohepta-dihydrotiazole derivatives, their preparation and use as anorectic drugs
NO20006029D0 (en) Pyrazoline derivatives, their preparation and use as pharmaceuticals
NO20005146D0 (en) Thienylazolylalkoxyethanamines, their preparation and their use as drugs
DK1095020T3 (en) 2-Aminopyridine derivatives, their use as pharmaceuticals and pharmaceutical compositions containing them
NO981522L (en) Amino acid derivatives, their preparation and use as endothelin antagonists
NO20006646L (en) Amino acid derivatives and drugs containing the same as active ingredient
DK0602028T3 (en) Aromatic sulfonamide derivatives, their use as enzyme inhibitors and pharmaceutical compositions and their contents
NO20005758L (en) Pharmaceutical preparation containing levothyroxine sodium
NO20040702L (en) Combined preparations containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances and the use thereof
NO951418D0 (en) Peptide derivatives, their preparation and use as therapeutics
NO960272D0 (en) Oxathiolanes, processes for their preparation and pharmaceutical compositions containing the same
DK0748222T3 (en) Cough suppressant composition containing cough suppressant and benzydamine
NO992998L (en) New analogues of camptotecin, use as drugs and pharmaceutical compositions containing them
CA2244357A1 (en) A novel pharmaceutical composition for inhalation containing cr 2039 (andolast)